Literature DB >> 22578922

Long-term hepatic safety of ambrisentan in patients with pulmonary arterial hypertension.

Ori Ben-Yehuda, David Pizzuti, Andrea Brown, Marcus Littman, Hunter Gillies, Noreen Henig, Tobias Peschel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22578922     DOI： 10.1016/j.jacc.2012.03.025

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN： 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  12 in total

Review 1.  An update on medical therapy for pulmonary arterial hypertension.

Authors:  Yan Wu; Dermot S O'Callaghan; Marc Humbert
Journal:  Curr Hypertens Rep       Date:  2013-12       Impact factor: 5.369

Review 2.  Ambrisentan: a review of its use in pulmonary arterial hypertension.

Authors:  Belinda N Rivera-Lebron; Michael G Risbano
Journal:  Ther Adv Respir Dis       Date:  2017-04-20       Impact factor: 4.031

Review 3.  New pharmacotherapies for pulmonary hypertension: where do they fit in?

Authors:  Aaron M Wolfson; Nathaniel Steiger; Mardi Gomberg-Maitland
Journal:  Curr Hypertens Rep       Date:  2014-12       Impact factor: 5.369

Review 4.  Comparative safety and tolerability of endothelin receptor antagonists in pulmonary arterial hypertension.

Authors:  Meghan Aversa; Sandra Porter; John Granton
Journal:  Drug Saf       Date:  2015-05       Impact factor: 5.606

Review 5.  Human immunodeficiency virus-associated pulmonary arterial hypertension.

Authors:  Christopher F Barnett; Priscilla Y Hsue
Journal:  Clin Chest Med       Date:  2013-04-08       Impact factor: 2.878

6.  A network meta-analysis for safety of endothelin receptor antagonists in pulmonary arterial hypertension.

Authors:  Yi-Jing Zhang; Na Wang; Zhi-Chun Gu; An-Hua Wei; An-Ni Cheng; Sha-Sha Fang; Hong-Li Du; Lin-Zhao Wang; Guo-Qing Zhang
Journal:  Cardiovasc Diagn Ther       Date:  2019-06

Review 7.  Clinical Adverse Effects of Endothelin Receptor Antagonists: Insights From the Meta-Analysis of 4894 Patients From 24 Randomized Double-Blind Placebo-Controlled Clinical Trials.

Authors:  Anhua Wei; Zhichun Gu; Juan Li; Xiaoyan Liu; Xiaofan Wu; Yi Han; Jun Pu
Journal:  J Am Heart Assoc       Date:  2016-10-26       Impact factor: 5.501

8.  Open label study of ambrisentan in patients with exercise pulmonary hypertension.

Authors:  Sergio A Segrera; Laurie Lawler; Alexander R Opotowsky; David Systrom; Aaron B Waxman
Journal:  Pulm Circ       Date:  2017-05-12       Impact factor: 3.017

Review 9.  Endothelin antagonism and its role in the treatment of hypertension.

Authors:  Rebecca C Moorhouse; David J Webb; David C Kluth; Neeraj Dhaun
Journal:  Curr Hypertens Rep       Date:  2013-10       Impact factor: 5.369

Review 10.  Novel Therapeutic Strategies for Reducing Right Heart Failure Associated Mortality in Fibrotic Lung Diseases.

Authors:  Ayodeji Adegunsoye; Matthew Levy; Olusegun Oyenuga
Journal:  Biomed Res Int       Date:  2015-10-25       Impact factor: 3.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.